Clinical trials: Neoplasia Prostate
Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma
Ivonescimab in the Treatment of Multiple Advanced Tumors
The goal of this clinical trial is to learn if Ivonescimab works to treat advanced rare tumors including cohort 1: PAGET's disease of scrotum with infiltrating sweat gland carcinoma.
- Conditions
- Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma
- Trial name
- NCT06683846
- Testing
- Ivocizumab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fudan University
Prostate Cancer
Phase III Radium 223 mCRPC-PEACE III
The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) by investigator assessment compared to enzalutamide single agent in…
- Trial name
- PEACE III (NCT02194842)
- Testing
- Ra223, Enzalutamide
- Where
- 64 sites in Belgium, Brazil and 10 more
- Volunteers
- 446 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide.
- Conditions
- Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT03016741
- Testing
- GnRH agonist/antagonist, Prednisone, Abiraterone Acetate
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Northwestern University
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Prostate Cancer
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00567580
- Testing
- PBRT, PLNRT, AA
- Where
- 460 sites in United States, Canada and 2 more
- Volunteers
- 1,792 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer, Sexual Dysfunction and Infertility
Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Male hormones can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide and finasteride may fight prostate cancer by reducing the production of male hormones.
- Trial name
- NCT00003323
- Testing
- finasteride, flutamide, quality-of-life assessment
- Where
- 43 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting
The Trans-Atlantic Prostate Group (TAPG) was established to examine the hypothesis that through a detailed retrospective analysis of outcome in a group of men with clinically localised prostate cancer at diagnosis, variables such…
- Trial name
- TAPG (NCT03912883)
- Volunteers
- 3,350 people
- Sponsor
- Queen Mary University of London
Prostate Cancer
Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care
Surgical implantation of Lyopreserved Placental Tissue (LPT) is FDA approved and has been used extensively in wound care. The use is expanding and more recently, LPT has been used in the management of diabetic foot ulcers, acute…
- Trial name
- NCT05366842
- Testing
- Stravix lyopreserved placental tissue (LPT), Radical prostatectomy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
Prostate Cancer
Trial of Iressa in Prostate Cancer Patients
This study is being carried out to see if ZD1839 is effective in treating prostate cancer after being diagnosed with an early rising PSA (prostate specific antigen) following surgery.
- Trial name
- NCT00265070
- Testing
- Gefitinib
- Where
- 4 sites in Canada
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Hyperalgesia, Pain
Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy
The primary aim is to determine whether perioperative NMDA-receptor antagonism has differential effects on postoperative pain, hyperalgesia and morbidity in younger and older patients.
- Conditions
- Hyperalgesia, Pain, Prostate Cancer
- Trial name
- NCT00188383
- Testing
- Amantadine
- Where
- Canada
- Volunteers
- 132 people
- Sponsor
- University Health Network, Toronto
Metastatic Castration-Resistant Prostate Cancer
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT01606982
- Testing
- MDV3100
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Prostate Cancer, Prostatic Neoplasms
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
Background: Prostate cancer is the second leading cause of cancer deaths in American men. Few options exist to create images of this type of cancer.
- Conditions
- Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer, Prostatic Cancer
- Trial name
- NCT03173924
- Testing
- 18F-NaF, 18F-DCFPyL, 18F-FDG
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Assessing The Impact Of Incorporating Charlson Comorbidity Scores On Patient Anxiety And Satisfaction
The purpose of this study was to determine whether providing patients with life expectancy (LE) information in the form of their Prostate Cancer Comorbidity Index (PCCI) scores impacted their decisional conflict or anxiety about…
- Trial name
- NCT03950180
- Testing
- Prostate Cancer Comorbidity Index (PCCI) score
- Volunteers
- 277 people
- Sponsor
- Benaroya Research Institute
Cancer, Breast Cancer
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
Add-Aspirin aims to assess whether regular aspirin use after standard curative therapy can prevent recurrence and improve survival in individuals with non-metastatic common tumours.
- Conditions
- Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT02804815
- Testing
- Aspirin 100mg, Aspirin 300mg
- Where
- 82 sites in Ireland, United Kingdom
- Volunteers
- 11,000 people
- Sponsor
- University College, London
Prostate Cancer
Effects of Anesthetic Technique on Immune and Inflammatory Systems Following Radical Prostatectomy
Several recently published retrospective studies show that regional anaesthesia (RA) can reduce cancer-related mortality following surgical treatment of colorectal, breast and prostate cancers and malignant melanoma.
- Trial name
- AIMS (NCT01367418)
- Testing
- Patient controlled analgesia (PCA), Thoracic Epidural Analgesia (TEA)
- Where
- Sweden
- Volunteers
- 26 people
- Sponsor
- Örebro University, Sweden
Prostate Cancer
Circulating Tumour Cells as Biomarkers to Predict Prostate Cancer Metastasis for Treatment Stratification of Cancer
The goal of this study is to establish the value of Circulating Tumour Cell (CTC) positivity in predicting post-RP treatment failure, including BCR and new lesions detected by cancer imaging.
- Trial name
- C-ProMeta-1 (NCT05533515)
- Testing
- CTC Blood Test
- Where
- United Kingdom
- Volunteers
- 330 people
- Sponsor
- Queen Mary University of London
Glioma, Glioma, Malignant
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
At the time of study termination, NUV-422-02 was a first-in-human, open-label, Phase 1 dose escalation study designed to evaluate the safety and efficacy of NUV-422.
- Conditions
- Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors
- Trial name
- NCT04541225
- Testing
- NUV-422
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- Nuvation Bio Inc.
Hormone-refractory Prostate Cancer
Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
This study is a phase I study of a cell based prostate cancer therapy, Autologous Lymphoid Effector Cells Specific Against Tumor-cells (ALECSAT).
- Trial name
- ALECSAT (NCT01422850)
- Testing
- ALECSAT
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- CytoVac A/S
Prostate Cancer
Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
The purpose of this study is to determine if continued treatment with Enzalutamide is effective in patients with metastatic prostate cancer.
- Trial name
- PLATO (NCT01995513)
- Testing
- Enzalutamide, Abiraterone, Prednisone
- Where
- 95 sites in United States, Australia and 9 more
- Volunteers
- 509 people
- Sponsor
- Pfizer
Information Support
The Effect of Information Support Program on Self-efficacy of Prostate Cancer Patients During Hormonal Therapy
The incidence rate of prostate cancer has been increasing rapidly in China in recent years. However, a large number of studies have shown that, patients with prostate cancer during hormonal therapy generally face the imbalance of…
- Trial name
- NCT04340713
- Testing
- information support program
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.